151 related articles for article (PubMed ID: 29446856)
1. Thyroid carcinoma producing β-human chorionic gonadotropin shows different clinical behavior.
Gu H; Sui S; Cui X; Han B; Zhang C; Qi M; Li C; Liu Z
Pathol Int; 2018 Apr; 68(4):207-213. PubMed ID: 29446856
[TBL] [Abstract][Full Text] [Related]
2. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathologic Features of Fatal Non-Anaplastic Follicular Cell-Derived Thyroid Carcinomas.
Xu B; Ibrahimpasic T; Wang L; Sabra MM; Migliacci JC; Tuttle RM; Ganly I; Ghossein R
Thyroid; 2016 Nov; 26(11):1588-1597. PubMed ID: 27480016
[TBL] [Abstract][Full Text] [Related]
4. Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
Song E; Jeon MJ; Oh HS; Han M; Lee YM; Kim TY; Chung KW; Kim WB; Shong YK; Song DE; Kim WG
Eur J Endocrinol; 2018 Sep; 179(3):135-142. PubMed ID: 29875289
[TBL] [Abstract][Full Text] [Related]
5. Discriminatory miRNAs for the Management of Papillary Thyroid Carcinoma and Noninvasive Follicular Thyroid Neoplasms with Papillary-Like Nuclear Features.
Jahanbani I; Al-Abdallah A; Ali RH; Al-Brahim N; Mojiminiyi O
Thyroid; 2018 Mar; 28(3):319-327. PubMed ID: 29378472
[TBL] [Abstract][Full Text] [Related]
6. Comparison of survival rates between papillary and follicular thyroid carcinomas among 36,725 patients.
Oyer SL; Fritsch VA; Lentsch EJ
Ann Otol Rhinol Laryngol; 2014 Feb; 123(2):94-100. PubMed ID: 24574464
[TBL] [Abstract][Full Text] [Related]
7. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute.
Chow SM; Law SC; Au SK; Leung TW; Chan PT; Mendenhall WM; Lau WH
Head Neck; 2002 Jul; 24(7):670-7. PubMed ID: 12112541
[TBL] [Abstract][Full Text] [Related]
8. DUSP6/MKP3 is overexpressed in papillary and poorly differentiated thyroid carcinoma and contributes to neoplastic properties of thyroid cancer cells.
Degl'Innocenti D; Romeo P; Tarantino E; Sensi M; Cassinelli G; Catalano V; Lanzi C; Perrone F; Pilotti S; Seregni E; Pierotti MA; Greco A; Borrello MG
Endocr Relat Cancer; 2013 Feb; 20(1):23-37. PubMed ID: 23132790
[TBL] [Abstract][Full Text] [Related]
9. The Flip Side of NIFTP: an Increase in Rates of Unfavorable Histologic Parameters in the Remainder of Papillary Thyroid Carcinomas.
Wong KS; Strickland KC; Angell TE; Nehs MA; Alexander EK; Cibas ES; Krane JF; Howitt BE; Barletta JA
Endocr Pathol; 2017 Jun; 28(2):171-176. PubMed ID: 28271380
[TBL] [Abstract][Full Text] [Related]
10. Aggressive variants of follicular cell-derived thyroid carcinoma: an overview.
Pizzimenti C; Fiorentino V; Ieni A; Martini M; Tuccari G; Lentini M; Fadda G
Endocrine; 2022 Oct; 78(1):1-12. PubMed ID: 35864338
[TBL] [Abstract][Full Text] [Related]
11. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
[TBL] [Abstract][Full Text] [Related]
12. Columnar cell variant of papillary thyroid carcinoma: a study of 10 cases with emphasis on CDX2 expression.
Sujoy V; Pinto A; Nosé V
Thyroid; 2013 Jun; 23(6):714-9. PubMed ID: 23488912
[TBL] [Abstract][Full Text] [Related]
13. Factors related to the survival of papillary and follicular thyroid carcinoma patients with distant metastases.
Lin JD; Huang MJ; Juang JH; Chao TC; Huang BY; Chen KW; Chen JY; Li KL; Chen JF; Ho YS
Thyroid; 1999 Dec; 9(12):1227-35. PubMed ID: 10646663
[TBL] [Abstract][Full Text] [Related]
14. Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients.
Loh KC; Greenspan FS; Gee L; Miller TR; Yeo PP
J Clin Endocrinol Metab; 1997 Nov; 82(11):3553-62. PubMed ID: 9360506
[TBL] [Abstract][Full Text] [Related]
15. Should subcentimeter non-invasive encapsulated, follicular variant of papillary thyroid carcinoma be included in the noninvasive follicular thyroid neoplasm with papillary-like nuclear features category?
Xu B; Farhat N; Barletta JA; Hung YP; Biase D; Casadei GP; Onenerk AM; Tuttle RM; Roman BR; Katabi N; Nosé V; Sadow P; Tallini G; Faquin WC; Ghossein R
Endocrine; 2018 Jan; 59(1):143-150. PubMed ID: 29204912
[TBL] [Abstract][Full Text] [Related]
16. [Clinicopathologic and molecular features of cribriform morular variant of papillary thyroid carcinoma].
Cui XJ; Zhao HO; Su P; Chen J; Zhang RY; Pan Y; Ouyang XM; Liu J; Zhang JQ; Yang Y; Yang R; Ding L; Liu ZY
Zhonghua Bing Li Xue Za Zhi; 2018 May; 47(5):354-359. PubMed ID: 29783802
[No Abstract] [Full Text] [Related]
17. A population-based analysis of survival factors in differentiated and medullary thyroid carcinoma.
Bhattacharyya N
Otolaryngol Head Neck Surg; 2003 Jan; 128(1):115-23. PubMed ID: 12574769
[TBL] [Abstract][Full Text] [Related]
18. Histology does not influence prognosis in differentiated thyroid carcinoma when accounting for age, tumour diameter, invasive growth and metastases.
Verburg FA; Mäder U; Luster M; Reiners C
Eur J Endocrinol; 2009 Apr; 160(4):619-24. PubMed ID: 19158232
[TBL] [Abstract][Full Text] [Related]
19. USP33 is a Biomarker of Disease Recurrence in Papillary Thyroid Carcinoma.
Jia M; Guo Y; Lu X
Cell Physiol Biochem; 2018; 45(5):2044-2053. PubMed ID: 29533940
[TBL] [Abstract][Full Text] [Related]
20. NONOPERATIVE MANAGEMENT OF DIFFERENTIATED THYROID CANCER IN CALIFORNIA: A POPULATION-LEVEL ANALYSIS OF 29,978 PATIENTS.
Kuo EJ; Wu JX; Li N; Zanocco KA; Yeh MW; Livhits MJ
Endocr Pract; 2017 Oct; 23(10):1262-1269. PubMed ID: 28816539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
